Stable expression of full length human androgen receptor in PC-3 prostate cancer cells enhances sensitivity to retinoic acid but not to 1α,25-dihydroxyvitamin D3

Prostate

Volumn 56, Issue 4, 2003, Pages 293-304

  Murthy, Shalini ^a   Marcelli, Marco ^a   Weigel, Nancy L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Androgen receptor; PC 3 cells; Prostate cancer; Retinoids; Vitamin D

Indexed keywords

ALITRETINOIN; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; CALCITRIOL; COMPLEMENTARY DNA; FLUTAMIDE; METRIBOLONE; RETINOIC ACID; RETINOID; VITAMIN D;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRETINOIN; TUMOR CELLS, CULTURED; VITAMIN D;

EID: 0042731868     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10261     Document Type: Article

References (40)

1. Feldman D, Zhao XY, Krishnan AV. Vitamin D and prostate cancer. Endocrinology 2000;141(1):5-9.
2. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 Dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993;132(5):1952-1960.
3. Koike M, Koshizuka K, Kawabata H, Yang R, Taub HE, Said J, Uskokovic M, Tsuruoka N, Koeffler HP. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: A unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines. Anticancer Res 1999;19(3A):1689-1697.
4. Zhuang SH, Schwartz GG, Cameron D, Burnstein KL. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol 1997;126(1):83-90.
5. Miller GJ, Stapleton GE, Hedlund TE, Moffat KA. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1995;1(9):997-1003.
6. Ly LH, Zhao XY, Holloway L, Feldman D. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 1999;140(5):2071-2076.
7. Jurutka PW, Whitfield GK, Hsieh JC, Thompson PD, Haussler CA, Haussler MR. Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev Endocr Metab Disord 2001;2(2):203-216.
8. Haussler M, Mangelsdorf DJ, Komm BS, Terpening CM, Yamazaki K, Allegretto EA, Baker AR, Shine J, McDonnell DP, Hughes M, et al. Molecular biology of the vitamin D hormone. In: Recent progress in hormone research. New York: Acacdemic Press, Inc.; 1988. pp 263-305.
9. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. Cancer Res 1992;52(3):515-520.
10. 1 accumulation. Endocrinology 1998;139(3):1197-1207.
11. Hsieh T, Wu JM. Induction of apoptosis and altered nuclear/cytoplasmic distribution of the androgen receptor and prostate-specific antigen by 1alpha,25-dihydroxyvitamin D3 in androgen-responsive LNCaP cells. Biochem Biophys Res Commun 1997;235(3):539-544.
12. Fife RS, Sledge GW Jr, Proctor C. Effects of vitamin D3 on proliferation of cancer cells in vitro. Cancer Lett 1997;120(1):65-69.
13. 1. Endocrinology 1997;138(4):1491-1497.
14. Blutt SE, McDonnell TJ, Polek TC, Weigel NL. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 2000;141(1):10-17.
15. Campbell MJ, Elstner E, Holden S, Uskokovic M, Koeffler HP. Inhibition of proliferation of prostate cancer cells by a 19-norhexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1, and E-cadherin. J Mol Endocrinol 1997;19(1):15-27.
16. Zhao XY, Ly LH, Peehl DM, Feldman D. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis-retinoic acid in LNCaP human prostate cancer cells. Endocrinology 1999;140(3):1205-1212.
17. Zhao XY, Ly LH, Peehl DM, Feldman D. 1Alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology 1997;138(8):3290-3298.
18. Esquenet M, Swinnen JV, Heyns W, Verhoeven G. Control of LNCaP proliferation and differentiation: Actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis-retinoic acid, and phenylacetate. Prostate 1996;28(3):182-194.
19. Goossens K, Esquenet M, Swinnen JV, Manin M, Rombauts W, Verhoeven G. Androgens decrease and retinoids increase the expression of insulin-like growth factor-binding protein-3 in LNcaP prostatic adenocarcinoma cells. Mol Cell Endocrinol 1999;155(1-2):9-18.
20. Tilley WD, Wilson CM, Marcelli M, McPhaul MJ. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 1990;50(17):5382-5386.
21. 1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology 2003;144(1):50-60.
22. Tilley WD, Marcelli M, Wilson JD, McPhaul MJ. Characterization and expression of a cDNA encoding the human androgen receptor. Proc Natl Acad Sci USA 1989;86(1):327-331.
23. Southern PJ, Berg P. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J Mol Appl Genet 1982;1(4):327-341.
24. Nawaz Z, Lonard DM, Smith CL, Lev-Lehman E, Tsai SY, Tsai MJ, O'Malley BW. The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Mol Cell Biol 1999;19(2):1182-1189.
25. Li P, Nicosia SV, Bai W. Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells. J Biol Chem 2001;276(23):20444-204450.
26. Allgood VE, Zhang Y, O'Malley BW, Weigel NL. Analysis of chicken progesterone receptor function and phosphorylation using an adenovirus-mediated procedure for high-efficiency DNA transfer. Biochemistry 1997;36(1):224-232.
27. Nazareth LV, Weigel NL. Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 1996;271(33):19900-19907.
28. Heisler LE, Evangelou A, Lew AM, Trachtenberg J, Elsholtz HP, Brown TJ. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol Cell Endocrinol 1997;126(1):59-73.
29. Segaert S, Garmyn M, Degreef H, Bouillon R. Retinoic acid modulates the anti-proliferative effect of 1,25-dihydroxyvitamin D3 in cultured human epidermal keratinocytes [published erratum appears in J Invest Dermatol 1997 Dec;109(6):821]. J Invest Dermatol 1997;109(1):46-54.
30. Anzano MA, Byers SW, Smith JM, Peer CW, Mullen LT, Brown CC, Roberts AB, Sporn MB. Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res 1994;54(17):4614-4617.
31. Pettersson F, Colston KW, Dalgleish AG. Differential and antagonistic effects of 9-cis-retinoic acid and vitamin D analogues on pancreatic cancer cells in vitro. Br J Cancer 2000;83(2):239-245.
32. Blutt SE, Polek TC, Stewart LV, Kattan MW, Weigel NL. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res 2000;60(4):779-782.
33. Schwartz GG, Hill CC, Oeler TA, Becich MJ, Bahnson RR. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo. Urology 1995;46(3):365-369.
34. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990;173(2):534-540.
35. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002;62(4):1008-1013.
36. Montgomery BT, Young CY, Bilhartz DL, Andrews PE, Prescott JL, Thompson NF, Tindall DJ. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate 1992;21(1):63-73.
37. Shen RSM, Dai J, Harris A, Kaminetzky D, Gao M, Burnstein KL, Nanus DM. Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase. Endocrinology 2000;141(6):1699-1704.
38. Yuan S, Trachtenberg J, Mills GB, Brown TJ, Xu F, Keating A. Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA [published erratum appears in Cancer Res 1995 Feb 1;55(3):719]. Cancer Res 1993;53(6):1304-13011.
39. Yang ES, Maiorino CA, Roos BA, Knight SR, Burnstein KL. Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer. Mol Cell Endocrinol 2002;186(1):69-79.
40. Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev 1998;7(5):391-395.